Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 3.25 EUR 2.85% Market Closed
Market Cap: 310.9m EUR

Inventiva SA
Other

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Inventiva SA
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Inventiva SA
PAR:IVA
Other
€68.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Other
-€20m
CAGR 3-Years
-33%
CAGR 5-Years
-50%
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Other
-€348k
CAGR 3-Years
43%
CAGR 5-Years
46%
CAGR 10-Years
-13%
DBV Technologies SA
PAR:DBV
Other
-$222k
CAGR 3-Years
45%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Other
-€2.3m
CAGR 3-Years
-6%
CAGR 5-Years
0%
CAGR 10-Years
N/A

Inventiva SA
Glance View

Market Cap
310.9m EUR
Industry
Biotechnology

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

IVA Intrinsic Value
6.1 EUR
Undervaluation 47%
Intrinsic Value
Price

See Also

What is Inventiva SA's Other?
Other
68.3m EUR

Based on the financial report for Dec 31, 2024, Inventiva SA's Other amounts to 68.3m EUR.

What is Inventiva SA's Other growth rate?
Other CAGR 1Y
1 240%

Over the last year, the Other growth was 1 240%.

Back to Top